Viltis Medica Sp. z o.o.

At Viltis Medica Sp. z o.o. in Trzebnica, clinical research is centered on immune system diseases, with a strong focus on uncontrolled moderate to severe eosinophilic asthma. The studies are designed to assess whether a new treatment approach can help improve symptom control and overall disease management for adults living with this challenging form of asthma.

• Evaluating a new therapy for eosinophilic asthma
• Comparing treatment effects against placebo
• Assessing efficacy in adults with persistent asthma symptoms

The site’s work in this area reflects a focused effort to advance better treatment options for people whose asthma remains difficult to control despite standard care.

Clinical trials at this health care site in Poland are exploring new ways to treat moderate to severe eosinophilic asthma, a respiratory condition linked to inflammation within the immune system. The research aims to determine whether an oral therapy can offer meaningful benefit for patients with ongoing asthma symptoms.

• Testing a potential new treatment for asthma
• Studying outcomes in adult participants with uncontrolled disease
• Supporting development of improved options for respiratory care

This small but targeted research portfolio highlights the site’s involvement in evaluating treatments intended to improve disease control and patient quality of life.